Go to main content

GCPharma

NEWS

The latest news
Updates on GC Pharma’s
Journey of supporting
Health and happiness.

전자공고 검색 입력 폼
Search
소식 상세 테이블 표
Title GC Pharma Reports Full Year 2020 Results
Date of registration 2021-02-09
Attachment File
Contents
Achieved double-digit growth over the previous year
 

YONGIN, South Korea, 9 February 2021 - GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited financial results for the year ended 31 December 2020.



Third-Quarter Reported Results(1)

Key Figures

Full Year 2020

Growth(2)

Total revenues

KRW 1,504.1 billion

+10.8%

Operating profit

KRW 50.3 billion

+20.6%

K-IFRS profit after taxation

KRW 89.3 billion

-

(1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations) 

(2) Results and percentages compare full financial year 2019  




Financial Highlights

● Delivered total revenue growth of 10.8% to KRW 1,504.1 billion (2019: 1,357.1 billion), and operation profit increased 20.6% to KRW 50.3 billion (2019: 41.7 billion) in the full year of 2020

● Unconsolidated revenues growth of 15.1% driven by strong sales performance across all segments

● Achieved double-digit turnover performance of subsidiaries, including Green Cross MS and Green Cross LabCell

● Local sales up 7.2% reflecting strong Vx and CHC segment performance. As uncertainty about full impact of COVID-19 remains, quarterly local sales continue to normalise

● Strong international sales performance of core businesses versus prior year, in particular, in line with the company’s expectations

● Achieved double-digit operation margin growth driven by increased overall local and international sales

● The company will continue to focus on improving profitability as well as expending R&D investment for future businesses



Short-term R&D Milestones

● Hunterase ICV Japan regulatory decision in Q1(Approved 22 January 2021)

● GreenGeneF China regulatory decision in Q1

● IVIG 10% US BLA submission in Q1



About GC Pharma
GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.

This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
 

# # #

List view

소식 리스트 테이블 표
Number Date of registration Title Attachment File Number of clicks
242 2023-12-06 GC Biopharma’s groundbreaking for the plasma fractionation plant in Indonesia 1552
241 2023-11-30 GC Biopharma establishes mRNA production facility in Hwasun, Korea 1090
240 2023-11-06 The World’s First “Recombinant Anthrax Vaccine”: GC Biopharma applies for MFDS Approval 1151
239 2023-10-05 FDA Grants Orphan Drug Designation to GC Biopharma’s Drug Candidate for Thrombotic Thrombocytopenic Purpura 1186
238 2023-08-30 GC Biopharma to organize “Donate Blood with Love”, a healthy way of giving back to the community 577
237 2023-08-25 GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics 307
236 2023-07-31 U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid) 906
235 2023-07-18 GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent 832
234 2023-06-02 GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia 327
233 2023-04-18 GC Biopharma celebrates 'World Hemophilia Day' 187
처음으로이전 10개

12345678910

다음 10개끝으로

이메일집단수집거부

GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일